MedAdvisor Limited ( (AU:MDR) ) has provided an update.
MedAdvisor Limited reported a 24.4% decline in group revenue for the first half of FY25, primarily due to reduced vaccine-related health program budgets from key US pharma clients. Despite this, the company achieved a gross margin increase to 61.3% and launched its Transformation 360 initiative, aimed at long-term value creation. The restructuring is expected to yield significant savings, and the company is well-positioned for future growth with a strong US pipeline and steady progress in the ANZ region. The strategic review process to maximize shareholder value is also advancing, with completion anticipated by June 2025.
More about MedAdvisor Limited
MedAdvisor Limited is a global pharmacy-driven patient engagement company that focuses on enhancing patient adherence and engagement through its innovative solutions. The company operates primarily in the healthcare industry, offering pharmacy services and patient engagement programs, with a significant market focus in the United States and Australia.
YTD Price Performance: -22.73%
Average Trading Volume: 532,008
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$93.83M
Learn more about MDR stock on TipRanks’ Stock Analysis page.